Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry

多学科综合基因组方法区分欧洲和非洲血统男性的致命性前列腺癌和惰性前列腺癌

• 批准号: 10253255
• 负责人: ANGELO Michael DE MARZO
• 金额: $ 64.84万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-10 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10253255
• 关键词: Address; Advocate; African; African American; Aging; Algorithms; American; Architecture; Automobile Driving; Autopsy; Baltimore; Bioinformatics; Biological Markers; Biometry; Biopsy; Cancer Etiology; Cancer Patient; Categories; Cessation of life; Clinical; Clinical Management; Collaborations; Collection; Coupled; DNA Methylation; DNA Sequence Rearrangement; DNA sequencing; Data Analyses; Data Set; Databases; Development; Diagnosis; Disease; Epidemiology; Equilibrium; Expression Profiling; Follow-Up Studies; Freezing; Frequencies; Genomic approach; Genomics; Gleason Grade for Prostate Cancer; Health; Health Professional; Immunohistochemistry; In Situ; In Situ Hybridization; Individual; Indolent; Intervention; Kinetics; Lesion; Localized Malignant Neoplasm; Longitudinal Studies; Longterm Follow-up; Malignant Neoplasms; Malignant neoplasm of prostate; Medical Oncology; Messenger RNA; Methods; Modernization; Molecular; Molecular Biology; Molecular Profiling; Monitor; Mutation; Nature; Neoplasm Metastasis; Nomograms; Organ; Outcome; PSA screening; Pathologic; Pathology; Pathway interactions; Patient Care; Patient-Focused Outcomes; Patients; Phase; Phenotype; Physicians; Population; Progressive Disease; Prostate Adenocarcinoma; Race; Radical Prostatectomy; Recurrence; Research Personnel; Resources; Risk; Risk stratification; Screening for Prostate Cancer; Sum; Technology; Testing; Therapeutic Intervention; Urology; Validation; Variant; Visceral; Work; base; biobank; cancer therapy; caucasian American; cell type; cohort; computer science; design; epigenomics; exome sequencing; experience; genome sequencing; genome-wide; improved; interdisciplinary approach; men; minimally invasive; mortality; multidisciplinary; multimodality; neoplastic cell; next generation; novel; novel marker; outcome forecast; outcome prediction; overtreatment; predictive signature; prostate cancer risk; public health relevance; racial disparity; screening; tool; transcriptome sequencing; treatment strategy; tumor; unnecessary treatment; whole genome

 DESCRIPTION (provided by applicant): There are several critical unmet needs in the management of localized prostate cancer. Central among them is the development of minimally invasive tools to distinguish localized cancers that are truly indolent from cancers that are progressive and potentially lethal. To address this key need, we first propose to perform an integrated, multi-dimensional genomic, epigenomic and expression analysis to uncover novel molecular pathways that characterize indolent vs. aggressive prostate cancers. In this approach we define indolent tumors as those screen detected (e.g. PSA screening) lesions that are Gleason score 6 (or less) that are organ confined at radical prostatectomy. We consider these tumors indolent as they do not appear capable of metastasis. In contrast, we equate Gleason score 8-10 tumors as "interval" or symptomatic since, even with primary treatment, these tumors often recur and metastasize at high frequencies. Additionally, we will validate our key markers/pathways discovered in this project using additional populations with long term outcomes. We hypothesize that our multi-modality genomic-based integrated approach, contrasting these two divergent tumor types, will reveal signatures that distinguish cancers with dichotomous phenotypes. We also hypothesize that these signatures will vary based on race and thus in parallel we will comprehensively characterize African American prostate cancers to reveal molecular features driving racial disparities in outcomes. We will validate the signatures obtained using large cohorts of cases with established outcomes including: (1) the Johns Hopkins Active surveillance cohort and (2) Prostate cancer cases from the BLSA (Baltimore Longitudinal Study of Aging), an observational cohort of men followed since 1954 with autopsy documented indolent or aggressive/lethal disease. We also propose that these signatures will be able to predict outcomes of cancers with indeterminate kinetics and propose to test this through analysis of cases of intermediate risk prostate cancer with long-term follow-up and known outcomes from Johns Hopkins and in collaboration with colleagues from Harvard, from the Physician's Health and Health Professionals follow-up studies. Together this work will yield highly relevant information that can be directly applied to the clinical management of localized prostate cancer. Specifically, it will yield an integrated signature that distinguishes localized - indolent tumors from localized tumors with lethal potential. Additionally we believe these signatures will be critical in determining treatment strategies for individuals with prostate cancers of indeterminate kinetics.

 描述（由申请人提供）：在局部前列腺癌的治疗中存在一些未满足的关键需求，其中最重要的是开发微创工具来区分真正惰性的局部癌症和进行性且可能致命的癌症。为了满足这一关键需求，我们首先建议进行集成的多维基因组、表观基因组和表达分析，以揭示表征惰性与侵袭性前列腺癌的新分子途径。在这种方法中，我们将惰性肿瘤定义为筛查检测到的肿瘤。 （例如 PSA 筛查）在根治性前列腺切除术中，Gleason 评分为 6（或更低）的病变局限于器官，我们认为这些肿瘤是惰性的，因为它们似乎不具有转移能力，相反，我们将 Gleason 评分为 8-10 的肿瘤视为“”。间隔期”或有症状，因为即使进行了初步治疗，这些肿瘤也经常以高频率复发和转移。此外，我们将使用具有长期结果的其他人群来验证我们在该项目中发现的关键标志物/途径。我们还发现，这些特征会因种族而异，因此我们将同时全面描述非裔美国人癌症的特征，以揭示导致结果种族差异的分子特征，我们将使用大量具有既定结果的病例来验证获得的特征，包括：（1） ) 约翰霍普金斯大学主动监测队列和 (2) 来自 BLSA 的前列腺癌病例（巴尔的摩纵向衰老研究），自 1954 年以来对尸检记录的惰性或侵袭性/致命疾病的男性观察队列，我们​​还提出这些特征将能够预测具有不确定动力学的癌症的结果，并建议通过分析来测试这一点。约翰·霍普金斯大学并与哈佛大学的同事、医师健康和健康专业人士合作，对中等风险前列腺癌病例进行了长期随访和已知结果后续研究。这项工作将产生高度相关的信息，可直接应用于局部前列腺癌的临床管理，特别是，它将产生区分局部前列腺癌的综合特征。 此外，我们相信这些特征对于确定具有不确定动力学的前列腺癌个体的治疗策略至关重要。

项目成果

Transcriptional landscape of PTEN loss in primary prostate cancer.

• DOI: 10.1186/s12885-021-08593-y
• 发表时间: 2021-07-26
• 期刊: BMC cancer
• 影响因子: 3.8
• 作者: Imada EL;Sanchez DF;Dinalankara W;Vidotto T;Ebot EM;Tyekucheva S;Franco GR;Mucci LA;Loda M;Schaeffer EM;Lotan T;Marchionni L
• 通讯作者: Marchionni L

Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.

• DOI: 10.1016/j.juro.2017.12.048
• 发表时间: 2018-06
• 期刊: The Journal of urology
• 作者: Bernstein AN;Shoag JE;Golan R;Halpern JA;Schaeffer EM;Hsu WC;Nguyen PL;Sedrakyan A;Chen RC;Eggener SE;Hu JC
• 通讯作者: Hu JC

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.

• DOI: 10.1038/pcan.2016.49
• 发表时间: 2017-03
• 期刊: Prostate cancer and prostatic diseases
• 影响因子: 4.8
• 作者: Benzon B;Zhao SG;Haffner MC;Takhar M;Erho N;Yousefi K;Hurley P;Bishop JL;Tosoian J;Ghabili K;Alshalalfa M;Glavaris S;Simons BW;Tran P;Davicioni E;Karnes RJ;Boudadi K;Antonarakis ES;Schaeffer EM;Drake CG;Feng F;Ross AE
• 通讯作者: Ross AE

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

• DOI: 10.1038/pcan.2016.72
• 发表时间: 2017-06
• 期刊: Prostate cancer and prostatic diseases
• 影响因子: 4.8
• 作者: Tosoian JJ;Druskin SC;Andreas D;Mullane P;Chappidi M;Joo S;Ghabili K;Agostino J;Macura KJ;Carter HB;Schaeffer EM;Partin AW;Sokoll LJ;Ross AE
• 通讯作者: Ross AE

Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.

• DOI: 10.1016/j.juro.2016.08.095
• 发表时间: 2017-03
• 期刊: The Journal of urology
• 作者: Maurice MJ;Sundi D;Schaeffer EM;Abouassaly R
• 通讯作者: Abouassaly R